Merck & Co. Inc. (NYSE: MRK) is -6.94% lower on its value in year-to-date trading and has touched a low of $71.71 and a high of $87.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRK stock was last observed hovering at around $75.79 in the last trading session, with the day’s gains setting it 0.33% off its average median price target of $97.00 for the next 12 months. It is also 28.86% off the consensus price target high of $107.00 offered by 23 analysts, but current levels are 3.65% higher than the price target low of $79.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $76.12, the stock is -0.43% and 0.42% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.46 million and changing 0.44% at the moment leaves the stock -4.50% off its SMA200. MRK registered -5.22% loss for a year compared to 6-month loss of -6.30%. The firm has a 50-day simple moving average (SMA 50) of $75.30 and a 200-day simple moving average (SMA200) of $79.04.
The stock witnessed a 2.63% gain in the last 1 month and extending the period to 3 months gives it a -6.14%, and is -1.09% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.26% over the week and 1.65% over the month.
Merck & Co. Inc. (MRK) has around 74000 employees, a market worth around $192.61B and $47.99B in sales. Current P/E ratio is 27.39 and Fwd P/E is 10.41. Profit margin for the company is 14.70%. Distance from 52-week low is 6.14% and -13.30% from its 52-week high. The company has generated returns on investments over the last 12 months (10.80%).
Merck & Co. Inc. (MRK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Merck & Co. Inc. (MRK) is a “Overweight”. 23 analysts offering their recommendations for the stock have an average rating of 1.90, where 5 rate it as a Hold and 3 think it is a “Overweight”. 15 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Merck & Co. Inc. is expected to release its quarterly report on 07/29/2021 and quarterly earnings per share for the current quarter are estimated at $1.64 with sales reaching $12.74B over the same period.The EPS is expected to shrink by -28.00% this year, but quarterly earnings will post 9.60% year-over-year. Quarterly sales are estimated to grow 5.70% in year-over-year returns.
Merck & Co. Inc. (MRK) Top Institutional Holders
3,446 institutions hold shares in Merck & Co. Inc. (MRK), with 2.2M shares held by insiders accounting for 0.09% while institutional investors hold 75.76% of the company’s shares. The shares outstanding are 2.53B, and float is at 2.53B with Short Float at 0.72%. Institutions hold 75.69% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 208.41 million shares valued at $17.05 billion. The investor’s holdings represent 8.24% of the MRK Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 195.02 million shares valued at $15.95 billion to account for 7.71% of the shares outstanding. The other top investors are State Street Corporation which holds 114.15 million shares representing 4.51% and valued at over $9.34 billion, while Geode Capital Management, LLC holds 1.66% of the shares totaling 42.1 million with a market value of $3.44 billion.
Merck & Co. Inc. (MRK) Insider Activity
A total of 22 insider transactions have happened at Merck & Co. Inc. (MRK) in the last six months, with sales accounting for 6 and purchases happening 16 times. The most recent transaction is an insider sale by FRAZIER KENNETH C ,the company’sChairman, President & CEO. SEC filings show that FRAZIER KENNETH C sold 280,000 shares of the company’s common stock on Nov 09 at a price of $81.42 per share for a total of $22.8 million. Following the sale, the insider now owns 0.41 million shares.
Merck & Co. Inc. disclosed in a document filed with the SEC on Oct 05 that Davis Robert M (EVP, Global Svcs & CFO) sold a total of 251,273 shares of the company’s common stock. The trade occurred on Oct 05 and was made at $81.03 per share for $20.36 million. Following the transaction, the insider now directly holds 0.17 million shares of the MRK stock.
Still, SEC filings show that on Aug 13, Chattopadhyay Sanat (Exe V-P & Pres. MMD) disposed off 10,380 shares at an average price of $83.01 for $0.86 million. The insider now directly holds 67,373 shares of Merck & Co. Inc. (MRK).
Merck & Co. Inc. (MRK): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 28.75% up over the past 12 months and Johnson & Johnson (JNJ) that is 17.06% higher over the same period. Sanofi (SNY) is 8.35% up on the 1-year trading charts. Short interest in the company’s stock has risen 1.79% from the last report on Mar 14, 2021 to stand at a total of 18.14 million short shares sold with a short interest ratio of 1.46.